Date: 2020-12-01

Type of information: Production agreement

Compound: VG901

Company: ViGeneron (DE) WuXi Advanced Therapies (USA - PA)

Therapeutic area: Ophthalmological diseases

Type agreement: development manufacturing

Action mechanism: gene therapy. VG901 targets a disease gene for Retinitis pigmentosa (RP), for which there is currently no approved treatment option. VG901 is developed from ViGeneron’s proprietary next generation vgAAV vector platform that allows a superior transduction of retinal cells and intravitreal, a less invasive treatment administration.

Disease: retinitis pigmentosa


  • On December 1, 2020, ViGeneron and WuXi Advanced Therapies, a leading Contract, Testing, Development and Manufacturing Organization (CTDMO), announced a strategic partnership to accelerate production for the clinical development of VG901, a next-generation ophthalmic gene therapy program. WuXi ATU will accelerate the development of VG901 by manufacturing, testing and making available the clinical trial grade treatment while leveraging its trusted, world-class AAV Suspension and Plasmid DNA platforms.

Financial terms:

Latest news:

Is general: Yes